Search research articles
Contact Us
Filters
Showing results (21-30 of 100) with videos related to
Page
of 10
Sort By:
EJNMMI Research
|
February 18, 2016
Impact of clinically tested NEP/ACE inhibitors on tumor uptake of [(111)In-DOTA]MG11-first estimates for clinical translation
Aikaterini Kaloudi, Berthold A Nock, Emmanouil Lymperis, et al.
Journal of Nuclear Cardiology : Official Publication of the American Society of Nuclear Cardiology
|
December 14, 2004
Prognostic value of stress Tc-99m tetrofosmin SPECT in patients with previous myocardial infarction: impact of scintigraphic extent of coronary artery disease
Abdou Elhendy, Arend F L Schinkel, Ron T van Domburg, et al.
Journal of Nuclear Cardiology : Official Publication of the American Society of Nuclear Cardiology
|
December 12, 2003
Risk stratification of patients after myocardial revascularization by stress Tc-99m tetrofosmin myocardial perfusion tomography
Abdou Elhendy, Arend F l Schinkel, Ron T van Domburg, et al.
The International Journal of Cardiovascular Imaging
|
April 22, 2006
Non-invasive diagnosis of in stent stenosis by stress 99m technetium tetrofosmin myocardial perfusion imaging
Abdou Elhendy, Arend F L Schinkel, Ron T van Domberg, et al.
Coronary Artery Disease
|
April 9, 2005
Post-systolic shortening during dobutamine stress echocardiography predicts cardiac survival in patients with severe left ventricular dysfunction
Riccardo Rambaldi, Jeroen J Bax, Vittoria Rizzello, et al.
Best Practice & Research. Clinical Gastroenterology
|
September 27, 2005
Endocrine tumours of the gastrointestinal tract. Peptide receptor radionuclide therapy
Jaap J M Teunissen, Dik J Kwekkeboom, Marion de Jong, et al.
Nuclear Medicine Communications
|
March 20, 2008
Therapy using labelled somatostatin analogues: comparison of the absorbed doses with 111In-DTPA-D-Phe1-octreotide and yttrium-labelled DOTA-D-Phe1-Tyr3-octreotide
Raffaella Barone, Stéphan Walrand, Mark Konijnenberg, et al.
Nature Reviews. Endocrinology
|
June 3, 2009
Peptide-receptor radionuclide therapy for endocrine tumors
Martijn van Essen, Eric P Krenning, Boen L R Kam, et al.
Journal of Nuclear Cardiology : Official Publication of the American Society of Nuclear Cardiology
|
November 29, 2012
What is the value of stress (99m)Tc-tetrofosmin myocardial perfusion imaging for the assessment of very long-term outcome in obese patients?
Rebecca S Korbee, Henk J Boiten, Machiel Ottenhof, et al.
Journal of Nuclear Cardiology : Official Publication of the American Society of Nuclear Cardiology
|
July 23, 2016
Cardiac stress imaging for the prediction of very long-term outcomes: Dobutamine stress echocardiography or dobutamine <sup>99m</sup>Tc-sestamibi SPECT?
Hendrik J Boiten, Ron T van Domburg, Marcel L Geleijnse, et al.
Page
of 10
Search research articles
Search
Showing results (21-30 of 100) with videos related to
Sort By:
Page
of 10
EJNMMI Research
|
February 18, 2016
Impact of clinically tested NEP/ACE inhibitors on tumor uptake of [(111)In-DOTA]MG11-first estimates for clinical translation
Aikaterini Kaloudi, Berthold A Nock, Emmanouil Lymperis, et al.
Journal of Nuclear Cardiology : Official Publication of the American Society of Nuclear Cardiology
|
December 14, 2004
Prognostic value of stress Tc-99m tetrofosmin SPECT in patients with previous myocardial infarction: impact of scintigraphic extent of coronary artery disease
Abdou Elhendy, Arend F L Schinkel, Ron T van Domburg, et al.
Journal of Nuclear Cardiology : Official Publication of the American Society of Nuclear Cardiology
|
December 12, 2003
Risk stratification of patients after myocardial revascularization by stress Tc-99m tetrofosmin myocardial perfusion tomography
Abdou Elhendy, Arend F l Schinkel, Ron T van Domburg, et al.
The International Journal of Cardiovascular Imaging
|
April 22, 2006
Non-invasive diagnosis of in stent stenosis by stress 99m technetium tetrofosmin myocardial perfusion imaging
Abdou Elhendy, Arend F L Schinkel, Ron T van Domberg, et al.
Coronary Artery Disease
|
April 9, 2005
Post-systolic shortening during dobutamine stress echocardiography predicts cardiac survival in patients with severe left ventricular dysfunction
Riccardo Rambaldi, Jeroen J Bax, Vittoria Rizzello, et al.
Best Practice & Research. Clinical Gastroenterology
|
September 27, 2005
Endocrine tumours of the gastrointestinal tract. Peptide receptor radionuclide therapy
Jaap J M Teunissen, Dik J Kwekkeboom, Marion de Jong, et al.
Nuclear Medicine Communications
|
March 20, 2008
Therapy using labelled somatostatin analogues: comparison of the absorbed doses with 111In-DTPA-D-Phe1-octreotide and yttrium-labelled DOTA-D-Phe1-Tyr3-octreotide
Raffaella Barone, Stéphan Walrand, Mark Konijnenberg, et al.
Nature Reviews. Endocrinology
|
June 3, 2009
Peptide-receptor radionuclide therapy for endocrine tumors
Martijn van Essen, Eric P Krenning, Boen L R Kam, et al.
Journal of Nuclear Cardiology : Official Publication of the American Society of Nuclear Cardiology
|
November 29, 2012
What is the value of stress (99m)Tc-tetrofosmin myocardial perfusion imaging for the assessment of very long-term outcome in obese patients?
Rebecca S Korbee, Henk J Boiten, Machiel Ottenhof, et al.
Journal of Nuclear Cardiology : Official Publication of the American Society of Nuclear Cardiology
|
July 23, 2016
Cardiac stress imaging for the prediction of very long-term outcomes: Dobutamine stress echocardiography or dobutamine <sup>99m</sup>Tc-sestamibi SPECT?
Hendrik J Boiten, Ron T van Domburg, Marcel L Geleijnse, et al.
Page
of 10